Selected research
Industry Research
Cutaneous Leishmaniasis Drugs Industry Research Report 2026
Market perspective
The global Cutaneous Leishmaniasis Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cutaneous Leishmaniasis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cutaneous Leishmaniasis Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Cutaneous Leishmaniasis Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cutaneous Leishmaniasis Drugs include GSK, Albert David, Bristol-Myers Squibb, Gilead Sciences, Knight Therapeutics, Profounda, Pfizer, Novartis and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cutaneous Leishmaniasis Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cutaneous Leishmaniasis Drugs Market by Company
GSK
Albert David
Bristol-Myers Squibb
Gilead Sciences
Knight Therapeutics
Profounda
Pfizer
Novartis
Sanofi
Xinhua Pharma
Cutaneous Leishmaniasis Drugs Segment by Type
Anti-Leishmanial/Antimicrobial Drugs
Antifungal Drugs
Pentavalent Antimonials
Cutaneous Leishmaniasis Drugs Segment by Application
Retail Pharmacy
Hospital
Others
Cutaneous Leishmaniasis Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cutaneous Leishmaniasis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cutaneous Leishmaniasis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cutaneous Leishmaniasis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cutaneous Leishmaniasis Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cutaneous Leishmaniasis Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cutaneous Leishmaniasis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Anti-Leishmanial/Antimicrobial Drugs
- Antifungal Drugs
- Pentavalent Antimonials
Applications
- Retail Pharmacy
- Hospital
- Others
Companies covered
- GSK
- Albert David
- Bristol-Myers Squibb
- Gilead Sciences
- Knight Therapeutics
- Profounda
- Pfizer
- Novartis
- Sanofi
- Xinhua Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cutaneous Leishmaniasis Drugs Market Size (2021-2032)
- 2.2.2 Global Cutaneous Leishmaniasis Drugs Sales (2021-2032)
- 2.2.3 Global Cutaneous Leishmaniasis Drugs Market Average Price (2021-2032)
- 2.3 Cutaneous Leishmaniasis Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Anti-Leishmanial/Antimicrobial Drugs
- 2.3.3 Antifungal Drugs
- 2.3.4 Pentavalent Antimonials
- 2.4 Cutaneous Leishmaniasis Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Retail Pharmacy
- 2.4.3 Hospital
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cutaneous Leishmaniasis Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cutaneous Leishmaniasis Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Cutaneous Leishmaniasis Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Cutaneous Leishmaniasis Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Cutaneous Leishmaniasis Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cutaneous Leishmaniasis Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cutaneous Leishmaniasis Drugs, Product Type & Application
- 3.8 Global Manufacturers of Cutaneous Leishmaniasis Drugs, Established Date
- 3.9 Global Cutaneous Leishmaniasis Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GSK
- 4.1.1 GSK Company Information
- 4.1.2 GSK Business Overview
- 4.1.3 GSK Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GSK Cutaneous Leishmaniasis Drugs Product Portfolio
- 4.1.5 GSK Recent Developments
- 4.2 Albert David
- 4.2.1 Albert David Company Information
- 4.2.2 Albert David Business Overview
- 4.2.3 Albert David Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Albert David Cutaneous Leishmaniasis Drugs Product Portfolio
- 4.2.5 Albert David Recent Developments
- 4.3 Bristol-Myers Squibb
- 4.3.1 Bristol-Myers Squibb Company Information
- 4.3.2 Bristol-Myers Squibb Business Overview
- 4.3.3 Bristol-Myers Squibb Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bristol-Myers Squibb Cutaneous Leishmaniasis Drugs Product Portfolio
- 4.3.5 Bristol-Myers Squibb Recent Developments
- 4.4 Gilead Sciences
- 4.4.1 Gilead Sciences Company Information
- 4.4.2 Gilead Sciences Business Overview
- 4.4.3 Gilead Sciences Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Gilead Sciences Cutaneous Leishmaniasis Drugs Product Portfolio
- 4.4.5 Gilead Sciences Recent Developments
- 4.5 Knight Therapeutics
- 4.5.1 Knight Therapeutics Company Information
- 4.5.2 Knight Therapeutics Business Overview
- 4.5.3 Knight Therapeutics Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Knight Therapeutics Cutaneous Leishmaniasis Drugs Product Portfolio
- 4.5.5 Knight Therapeutics Recent Developments
- 4.6 Profounda
- 4.6.1 Profounda Company Information
- 4.6.2 Profounda Business Overview
- 4.6.3 Profounda Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Profounda Cutaneous Leishmaniasis Drugs Product Portfolio
- 4.6.5 Profounda Recent Developments
- 4.7 Pfizer
- 4.7.1 Pfizer Company Information
- 4.7.2 Pfizer Business Overview
- 4.7.3 Pfizer Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer Cutaneous Leishmaniasis Drugs Product Portfolio
- 4.7.5 Pfizer Recent Developments
- 4.8 Novartis
- 4.8.1 Novartis Company Information
- 4.8.2 Novartis Business Overview
- 4.8.3 Novartis Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Novartis Cutaneous Leishmaniasis Drugs Product Portfolio
- 4.8.5 Novartis Recent Developments
- 4.9 Sanofi
- 4.9.1 Sanofi Company Information
- 4.9.2 Sanofi Business Overview
- 4.9.3 Sanofi Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Sanofi Cutaneous Leishmaniasis Drugs Product Portfolio
- 4.9.5 Sanofi Recent Developments
- 4.10 Xinhua Pharma
- 4.10.1 Xinhua Pharma Company Information
- 4.10.2 Xinhua Pharma Business Overview
- 4.10.3 Xinhua Pharma Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Xinhua Pharma Cutaneous Leishmaniasis Drugs Product Portfolio
- 4.10.5 Xinhua Pharma Recent Developments
5 Global Cutaneous Leishmaniasis Drugs Market Scenario by Region
- 5.1 Global Cutaneous Leishmaniasis Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cutaneous Leishmaniasis Drugs Sales by Region: 2021-2032
- 5.2.1 Global Cutaneous Leishmaniasis Drugs Sales by Region: 2021-2026
- 5.2.2 Global Cutaneous Leishmaniasis Drugs Sales by Region: 2027-2032
- 5.3 Global Cutaneous Leishmaniasis Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Cutaneous Leishmaniasis Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Cutaneous Leishmaniasis Drugs Revenue by Region: 2027-2032
- 5.4 North America Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country
- 5.4.1 North America Cutaneous Leishmaniasis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cutaneous Leishmaniasis Drugs Sales by Country (2021-2032)
- 5.4.3 North America Cutaneous Leishmaniasis Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country
- 5.5.1 Europe Cutaneous Leishmaniasis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cutaneous Leishmaniasis Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Cutaneous Leishmaniasis Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cutaneous Leishmaniasis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cutaneous Leishmaniasis Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cutaneous Leishmaniasis Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country
- 5.7.1 South America Cutaneous Leishmaniasis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cutaneous Leishmaniasis Drugs Sales by Country (2021-2032)
- 5.7.3 South America Cutaneous Leishmaniasis Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cutaneous Leishmaniasis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cutaneous Leishmaniasis Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cutaneous Leishmaniasis Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Cutaneous Leishmaniasis Drugs Sales by Type (2021-2032)
- 6.1.1 Global Cutaneous Leishmaniasis Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Cutaneous Leishmaniasis Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Cutaneous Leishmaniasis Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Cutaneous Leishmaniasis Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Cutaneous Leishmaniasis Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cutaneous Leishmaniasis Drugs Sales by Application (2021-2032)
- 7.1.1 Global Cutaneous Leishmaniasis Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Cutaneous Leishmaniasis Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Cutaneous Leishmaniasis Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Cutaneous Leishmaniasis Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Cutaneous Leishmaniasis Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cutaneous Leishmaniasis Drugs Value Chain Analysis
- 8.1.1 Cutaneous Leishmaniasis Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cutaneous Leishmaniasis Drugs Production Mode & Process
- 8.2 Cutaneous Leishmaniasis Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cutaneous Leishmaniasis Drugs Distributors
- 8.2.3 Cutaneous Leishmaniasis Drugs Customers
9 Global Cutaneous Leishmaniasis Drugs Analyzing Market Dynamics
- 9.1 Cutaneous Leishmaniasis Drugs Industry Trends
- 9.2 Cutaneous Leishmaniasis Drugs Industry Drivers
- 9.3 Cutaneous Leishmaniasis Drugs Industry Opportunities and Challenges
- 9.4 Cutaneous Leishmaniasis Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst